Erika P. Hamilton, MD, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.
Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.
Despite the efficacy seen with endocrine agents and the presence of CDK4/6 inhibitors in the metastatic setting, the need for studies examining agents such as OP-1250 is due to the ability of tumors to develop resistance to therapies, Hamilton explains. Some endocrine agents that are available following treatment with CDK4/6 inhibitors are not as effective as desired, Hamilton says.
The interest in OP-1250 derives from the fact that it is both an antagonist and a degrader compared with other endocrine agents that are not complete antagonists, according to Hamilton. Because other endocrine agents provide some antagonist activity and some agonist activity, questions remain regarding whether they are as effective as they could be, Hamilton explains.
OP-1250 is being examined in patients who have previously been treated with endocrine agents, CDK4/6 inhibitors, and even chemotherapy; it is an oral drug that is taken once daily, which is convenient for patients, Hamilton concludes.